Celeste joined Catamaran as Senior Vice President, Research, in June 2020. She brings more than 16 years of experience in research and drug discovery in biotech and large pharma. Prior to Catamaran, Celeste served as Vice President of Cell Therapy at Obsidian Therapeutics where she led research strategy and execution through successful transition from seed funding through Series A to pharma partnership and internal pipeline build. Prior to Obsidian, Celeste served as a Research leader in Oncology and Immuno-Oncology at Novartis for 12 years, driving programs in Cell Therapy and Biologics spanning target discovery through IND submission. Celeste conducted her postdoctoral training at Harvard Medical School, where she studied cancer cell signaling. Celeste holds a PhD in Biochemistry and Molecular Biology from the University of Chicago and a BA in Biology from Carleton College.